Dr. Bismar has published more than 115 peer reviewed publications mostly in prostate cancer biomarkers and genomic signatures and currently has active collaborations with several national and international investigators. His research employs multiple platforms including gene expression, copy number alteration and whole exome/genome sequencing of somatic and germ line mutations in association to invitro/in-vivo manipulation. as well as summarizing his research.
Dr. Bismar research focuses mainly on prostate cancer in two areas; low-intermediate disease whose patients are enrolled in Active surveillance programs with the aim to develop clinical signatures to guide urologists on follow-up protocols and when to implement definite therapy, thus promoting “Precision Active Surveillance guidelines”. The second area is related to the development of neuroendocrine prostate cancer post hormonal and radiotherapy, where his main objective is to understand the genomic underlying in increased risk for such differentiation post hormonal and radiotherapy. |
